Key features and details
- Rabbit polyclonal to NRAS - C-terminal
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
Product nameAnti-NRAS antibody - C-terminal
See all NRAS primary antibodies
DescriptionRabbit polyclonal to NRAS - C-terminal
Specificityab167136 is predicted to not cross-react with H-RAS.
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide, corresponding to 15 amino acids from near the C terminus of Human NRAS (NP_002515).
- 293 cell lysate.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.2
Preservative: 0.02% Sodium azide
Constituent: 99% PBS
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab167136 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 0.5 - 2 µg/ml. Predicted molecular weight: 21 kDa.|
FunctionRas proteins bind GDP/GTP and possess intrinsic GTPase activity.
Involvement in diseaseDefects in NRAS are a cause of juvenile myelomonocytic leukemia (JMML) [MIM:607785]. JMML is a pediatric myelodysplastic syndrome that constitutes approximately 30% of childhood cases of myelodysplastic syndrome (MDS) and 2% of leukemia.
Defects in NRAS are the cause of Noonan syndrome type 6 (NS6) [MIM:613224]. A syndrome characterized by facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears. Other features can include short stature, a short neck with webbing or redundancy of skin, cardiac anomalies, deafness, motor delay and variable intellectual deficits.
Sequence similaritiesBelongs to the small GTPase superfamily. Ras family.
modificationsPalmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
Cellular localizationCell membrane. Golgi apparatus membrane. Shuttles between the plasma membrane and the Golgi apparatus.
- Information by UniProt
- ALPS4 antibody
- AV095280 antibody
- GTPase NRas antibody
Western Blot of A431 cell lysate labeling NRAS with Anti-NRAS antibody - C-terminal (ab167136) at (1) 1 and (2) 2µg/ml.
Lane 1 : Anti-NRAS antibody - C-terminal (ab167136) at 1 µg/ml
Lane 2 : Anti-NRAS antibody - C-terminal (ab167136) at 2 µg/ml
All lanes : 293 cell lysate
Lysates/proteins at 15 µg per lane.
Predicted band size: 21 kDa
ab167136 has been referenced in 1 publication.
- Martinez-Useros J et al. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept. PLoS One 12:e0182044 (2017). PubMed: 28763470